News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
95,444 Results
Type
Article (6913)
Company Profile (40)
Press Release (88491)
Multimedia
Podcasts (6)
Webinars (2)
Section
Business (28397)
Career Advice (131)
Deals (4118)
Drug Delivery (32)
Drug Development (14369)
Employer Resources (15)
FDA (2925)
Job Trends (2175)
News (50336)
Policy (6114)
Tag
2024 BioForest Digital (1)
2024 Bio NC Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
2026 Pharm Country Premier (1)
Academia (435)
Accelerated approval (3)
Adcomms (7)
Allergies (32)
Alliances (9212)
ALS (13)
Alzheimer's disease (264)
Antibody-drug conjugate (ADC) (45)
Approvals (2923)
Artificial intelligence (46)
Autoimmune disease (9)
Automation (3)
Bankruptcy (20)
Best Places to Work (1852)
BIOSECURE Act (16)
Biosimilars (78)
Biotechnology (27)
Bladder cancer (22)
Brain cancer (6)
Breast cancer (54)
Cancer (484)
Cardiovascular disease (23)
Career advice (114)
Career pathing (3)
CAR-T (21)
Cell therapy (86)
Cervical cancer (3)
Clinical research (11746)
Collaboration (201)
Compensation (46)
Complete response letters (9)
COVID-19 (566)
CRISPR (5)
C-suite (56)
Cystic fibrosis (13)
Data (459)
Denatured (2)
Depression (6)
Diabetes (37)
Diagnostics (586)
Digital health (3)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (26)
Drug pricing (25)
Drug shortages (1)
Duchenne muscular dystrophy (27)
Earnings (9809)
Editorial (6)
Employer branding (3)
Employer resources (13)
Events (12239)
Executive appointments (127)
FDA (3279)
Featured Employer (9)
Frontotemporal dementia (1)
Funding (153)
Gene editing (25)
Generative AI (6)
Gene therapy (88)
GLP-1 (110)
Government (1338)
Grass and pollen (1)
Guidances (12)
Healthcare (1986)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (44)
Indications (9)
Infectious disease (602)
Inflammatory bowel disease (48)
Inflation Reduction Act (4)
Influenza (15)
Intellectual property (12)
Interviews (12)
IPO (1892)
IRA (13)
Job creations (397)
Job search strategy (110)
Kidney cancer (2)
Labor market (2)
Layoffs (57)
Leadership (1)
Legal (566)
Liver cancer (13)
Lung cancer (78)
Lymphoma (31)
Machine learning (1)
Management (3)
Manufacturing (118)
MASH (12)
Medical device (1226)
Medtech (1227)
Mergers & acquisitions (2326)
Metabolic disorders (88)
Multiple sclerosis (19)
NASH (2)
Neurodegenerative disease (18)
Neuropsychiatric disorders (1)
Neuroscience (342)
NextGen: Class of 2025 (702)
Non-profit (354)
Northern California (493)
Now hiring (11)
Obesity (32)
Opinion (49)
Ovarian cancer (20)
Pain (11)
Pancreatic cancer (13)
Parkinson's disease (10)
Partnered (3)
Patents (32)
Patient recruitment (19)
Peanut (21)
People (8169)
Pharmaceutical (11)
Pharmacy benefit managers (2)
Phase I (3859)
Phase II (4870)
Phase III (4331)
Pipeline (308)
Policy (52)
Postmarket research (301)
Preclinical (1502)
Press Release (66)
Prostate cancer (19)
Psychedelics (5)
Radiopharmaceuticals (38)
Rare diseases (76)
Real estate (937)
Recruiting (6)
Regulatory (4874)
Reports (11)
Research institute (392)
Resumes & cover letters (11)
RNA editing (1)
RSV (11)
Schizophrenia (11)
Series A (36)
Series B (13)
Service/supplier (3)
Sickle cell disease (8)
Southern California (519)
Special edition (3)
Spinal muscular atrophy (21)
Sponsored (11)
Startups (586)
State (1)
Stomach cancer (3)
Supply chain (11)
Tariffs (12)
The Weekly (4)
United States (4333)
Vaccines (189)
Venture capitalists (7)
Weight loss (16)
Women's health (3)
Date
Today (16)
Last 7 days (136)
Last 30 days (504)
Last 365 days (6389)
2025 (2035)
2024 (6664)
2023 (7104)
2022 (9484)
2021 (9781)
2020 (8434)
2019 (5982)
2018 (4607)
2017 (5149)
2016 (4693)
2015 (5419)
2014 (3817)
2013 (2942)
2012 (3029)
2011 (3191)
2010 (2606)
Location
Africa (95)
Alabama (11)
Alaska (2)
Arizona (12)
Arkansas (2)
Asia (7766)
Australia (924)
California (1203)
Canada (241)
China (175)
Colorado (41)
Connecticut (26)
Delaware (40)
Europe (14034)
Florida (140)
Georgia (19)
Idaho (13)
Illinois (53)
India (12)
Indiana (40)
Iowa (2)
Japan (37)
Kansas (3)
Kentucky (9)
Louisiana (2)
Maine (5)
Maryland (320)
Massachusetts (855)
Michigan (27)
Minnesota (45)
Mississippi (1)
Missouri (15)
Montana (5)
Nebraska (1)
Nevada (4)
New Hampshire (3)
New Jersey (465)
New Mexico (4)
New York (329)
North Carolina (203)
North Dakota (7)
Northern California (493)
Ohio (41)
Oklahoma (7)
Oregon (3)
Pennsylvania (194)
Puerto Rico (1)
Rhode Island (5)
South America (135)
South Carolina (2)
Southern California (519)
Tennessee (3)
Texas (156)
Utah (24)
Virginia (18)
Washington D.C. (6)
Washington State (94)
Wisconsin (8)
95,444 Results for "fujifilm kyowa kirin biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA
April 9, 2025
·
7 min read
Immunology and inflammation
Amgen, Kyowa Kirin’s Rocatinlimab Picks Up Steam With Late-Stage Atopic Dermatitis Win
In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the antibody’s efficacy in that study to be underwhelming.
March 10, 2025
·
2 min read
·
Tristan Manalac
Business
Kyowa Kirin Announces Board Approval for Construction of New Biologics Manufacturing Plant in Sanford, NC
Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company based in Japan, announced that its board of directors has approved plans to invest up to $530 million to build a new, state-of-the-art manufacturing facility in Sanford, North Carolina.
June 10, 2024
·
4 min read
Press Releases
Kyowa Kirin Announces Late-Breaking Abstract Presentation at the American Academy of Dermatology Annual Meeting 2025
February 26, 2025
·
4 min read
Press Releases
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
March 10, 2025
·
16 min read
Press Releases
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies
December 9, 2024
·
2 min read
Business
How Kyowa Kirin is Giving Employees a Voice in the Company’s Future
Five years ago, Kyowa Kirin set out to expand its North America operations, adding new employees and capabilities at a rapid pace. The Human Resources team ensures employee input is central to managing that growth and nurturing a culture to support it
December 7, 2023
·
4 min read
·
Britt Byers, Senior Vice President of Human Resources, Kyowa Kirin North America
Press Releases
Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs
February 5, 2025
·
14 min read
Press Releases
Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe
January 30, 2025
·
7 min read
Cancer
Kura Signs Leukemia Pact with Kyowa Kirin After Losing Race to Syndax
The agreement will give Kura enough capital to support the development and launch of its menin inhibitor ziftomenib.
November 21, 2024
·
2 min read
·
Tristan Manalac
1 of 9,545
Next
